Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2008

View Archived Issues

Algeta initiates phase I BC1-08 clinical trial of Alpharadin in HRPC

Methadone induces apoptosis in leukemia cells, including resistant lines

AMPK agonist enhances exercise endurance without exercise training

Bacteria expressing NadA from N. meningitidis induces humoral responses

Rapamycin reverses deficits in tuberous sclerosis model

PLx Pharma reports positive results with proprietary NSAID-phosphatydylcholine complexes

New compounds for the treatment of cardiovascular disorders claimed in recent patents

Novel PDE4/TNF-alpha release inhibitors emerge from Leo Pharma R&D

Recent patents disclose novel agents for schizophrenia, anxiety, etc.

FDA approves PolyMedix's IND application to initiate phase I clinical trials of PMX-60056

Epix initiates phase IIb right-heart catheter study of PRX-08066 in PH associated with COPD

Enrollment target reached for interim analysis of phase III trials of Viprinex

Positive results from MT-02 phase II/III clinical study of house dust mite vaccine tablet

Allon reports positive results from pharmacokinetics study of AL-108 and AL-208

Peplin completes enrollment in PEP005-015 phase IIb clinical trial of PEP-005 gel in AK

Protectan CBLB-502 demonstrates efficacy in animal models of tourniquet injury

EMEA presents an update on reports of PML in MS patients treated with Tysabri

CSL to acquire Talecris Biotherapeutics

CPEX signs manufacturing agreement for Nasulin with DPT Laboratories

Lexicon initiates formal preclinical development of LX-7101 for glaucoma

Topical Homspera accelerates wound healing in animal models

ImClone initiates treatment in phase III clinical trial of IMC-1121B in breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...